

University of Massachusetts Medical School

**eScholarship@UMMS**

---

COVID-19 Publications by UMMS Authors

---

2020-04-07

## SARS-CoV-2

Jeremy Luban

*University of Massachusetts Medical School*

**Let us know how access to this document benefits you.**

Follow this and additional works at: <https://escholarship.umassmed.edu/covid19>



Part of the [Immunology and Infectious Disease Commons](#), [Infectious Disease Commons](#), [Virology Commons](#), and the [Virus Diseases Commons](#)

---


### Repository Citation

Luban J. (2020). SARS-CoV-2. COVID-19 Publications by UMMS Authors. <https://doi.org/10.13028/psdv-3088>. Retrieved from <https://escholarship.umassmed.edu/covid19/7>

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in COVID-19 Publications by UMMS Authors by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).


# SARS-CoV-2

April 7<sup>th</sup>, 2020






NICK WOOLRIDGE CC BY-ND 4.0

Jeremy Luban







nextstrain.org



Wölfel, R., et al. (2020). Virological assessment of 9 hospitalized patients with COVID-2019. Nature. in press

### Nasal swabs

average RNA load  $7 \times 10^5$ ; max  $7 \times 10^8$   
17% virus positive in 1st week

### Sputum

average RNA load  $7 \times 10^6$ ; max  $2 \times 10^9$   
83% virus positive in 1st week

### Virus isolation

None positive after day 8 or when viral load  $<10^6$




### Virus replication in upper respiratory tract

sgRNA in swab

point mutation in swab vs sputum

### Seroconversion


50% + by day 7; 100% by day 14  
all had neutralizing abs



Pre-cleaved?


## Where is SARS-CoV-2 within virus taxonomy?

SARS-CoV-2 is a Beta-Coronavirus in the order *Nidovirales*



produce 3' co-terminal **nested** subgenomic mRNA's during infection


## Which Coronaviruses infect humans?





## Are coronaviruses endemic among humans?

Human coronavirus circulation in the United States 2014–2017



Up to 30% of seasonal common cold

2-4 yr peaks


Why do they keep returning?


**Weak immunity vs strain variants**

J Clin Virol 101:52

# Human coronavirus circulation & reservoirs pre-COVID-19

	MERS-CoV	DPP4
	<b>SARS-CoV</b>	ACE2
Circulate globally	HCoV-NL63	ACE2
	HCoV-HKU1	9-O-Ac-Sialic Acid
Common cold	HCoV-OC43	9-O-Ac-Sialic Acid
	HCoV-229E	APN





**Bats are the main reservoir  
for SARS-like viruses**


**500 novel coronaviruses  
in bats in China**

**50 in the SARS family**

**Predicts future outbreaks**



## Bat is SARS-CoV-2 reservoir pangolin possible intermediate



Overall, bat viruses closer to SARS-CoV-2 than are pangolin viruses

Critical residues in S protein are more similar between human and pangolin viruses

Pangolin ACE2 closer to human ACE2 than is bat ACE2

# Some differences between SARS-CoV and SARS-CoV-2



SARS-CoV

SARS-CoV-2

Cases

8,096

1,346,299 (166x)

Deaths

774

74,679 (96x)

Asymptomatic  
infection

No

Yes (50%?)

Upper airway  
virus replication


No

Yes

Polybasic cleavage site  
in S protein



No

Yes




Cell in press

<https://doi.org/10.1016/j.cell.2020.02.052>






# SARS-CoV-2




NICK WOOLRIDGE CC BY-ND 4.0



## Lifecycle of SARS-CoV-2

# SARS-CoV-2 genome: 30kB plus-sense RNA



**How does one RNA make 30 proteins in a eukaryotic cell?**

encodes 2 polyproteins


encodes 2 proteases

ribosomal frameshift

discontinuous transcription/programmed recombination




# Ribosomal frameshift produces pp1a + pp1ab




**slippery sequence** just before the replicase 1a stop codon

RNA stem-loop with **pseudoknot**

## Two major polyproteins: pp1a + pp1ab




## Two proteases



**nsp5:**  
main protease  
(Mpro, 3CL)  
cleavage sites = ∇

# SARS-CoV-2 has an amazing set of proteins



Antagonists of the immune system (e.g., 2'-O-MTase; nsp16)


RNA replication machinery (RdRP; nsp12)

Replication proof-reading (3'-5' exonuclease; nsp14)


RNA metabolism in the cytoplasm (7-methyltransferase; nsp14)

## A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

David E. Gordon<sup>1,2,3,4</sup>, Gwendolyn M. Jang<sup>1,2,3,4</sup>, Mehdi Bouhaddou<sup>1,2,3,4</sup>, Jiewei Xu<sup>1,2,3,4</sup>, Kirsten Obernier<sup>1,2,3,4</sup>, Matthew J. O'Meara<sup>5</sup>, Jeffrey Z. Guo<sup>1,2,3,4</sup>, Danielle L. Swaney<sup>1,2,3,4</sup>, Tia A. Tummino<sup>1,2,6</sup>, Ruth Hüttenhain<sup>1,2,3,4</sup>, Robyn M. Kaake<sup>1,2,3,4</sup>, Alicia L. Richards<sup>1,2,3,4</sup>, Beril Tutuncuoglu<sup>1,2,3,4</sup>, Helene Foussard<sup>1,2,3,4</sup>, Jyoti Batra<sup>1,2,3,4</sup>, Kelsey Haas<sup>1,2,3,4</sup>, Maya Modak<sup>1,2,3,4</sup>, Minkyu Kim<sup>1,2,3,4</sup>, Paige Haas<sup>1,2,3,4</sup>, Benjamin J. Polacco<sup>1,2,3,4</sup>, Hannes Braberg<sup>1,2,3,4</sup>, Jacqueline M. Fabius<sup>1,2,3,4</sup>, Manon Eckhardt<sup>1,2,3,4</sup>, Margaret Soucheray<sup>1,2,3,4</sup>, Melanie J. Bennett<sup>1,2,3,4</sup>, Merve Cakir<sup>1,2,3,4</sup>, Michael J. McGregor<sup>1,2,3,4</sup>, Qiongyu Li<sup>1,2,3,4</sup>, Zun Zar Chi Naing<sup>1,2,3,4</sup>, Yuan Zhou<sup>1,2,3,4</sup>, Shiming Peng<sup>1,2,6</sup>, Ilsa T. Kirby<sup>1,4,7</sup>, James E. Melnyk<sup>1,4,7</sup>, John S. Chiorba<sup>1,4,7</sup>, Kevin Lou<sup>1,4,7</sup>, Shizhong A. Dai<sup>1,4,7</sup>, Wenqi Shen<sup>1,4,7</sup>, Ying Shi<sup>1,4,7</sup>, Ziyang Zhang<sup>1,4,7</sup>, Inigo Barrio-Hernandez<sup>8</sup>, Danish Memon<sup>8</sup>, Claudia Hernandez-Armenta<sup>8</sup>, Christopher J.P. Mathy<sup>1,2,9,10</sup>, Tina Perica<sup>1,2,9</sup>, Kala B. Pilla<sup>1,2,9</sup>, Sai J. Ganesan<sup>1,2,9</sup>, Daniel J. Saltzberg<sup>1,2,9</sup>, Rakesh Ramachandran<sup>1,2,9</sup>, Xi Liu<sup>1,2,6</sup>, Sara B. Rosenthal<sup>11</sup>, Lorenzo Calviello<sup>12</sup>, Srivats Venkataramanan<sup>12</sup>, Yizhu Lin<sup>12</sup>, Stephanie A. Wankowicz<sup>1,9,13</sup>, Markus Bohn<sup>6</sup>, Raphael Trenker<sup>14</sup>, Janet M. Young<sup>15</sup>, Devin Cavero<sup>16,3</sup>, Joe Hiatt<sup>16,3</sup>, Theo Roth<sup>16,3</sup>, Ujjwal Rathore<sup>16,3</sup>, Advait Subramanian<sup>1,17</sup>, Julia Noack<sup>1,17</sup>, Mathieu Hubert<sup>18</sup>, Ferdinand Roesch<sup>19</sup>, Thomas Vallet<sup>19</sup>, Björn Meyer<sup>19</sup>, Kris M. White<sup>20</sup>, Lisa Miorin<sup>20</sup>, David Agard<sup>1,21</sup>, Michael Emerman<sup>22</sup>, Davide Ruggero<sup>23,24,4</sup>, Adolfo García-Sastre<sup>20</sup>, Natalia Jura<sup>1,14,4</sup>, Mark von Zastrow<sup>1,2,4,25</sup>, Jack Taunton<sup>1,2,4</sup>, Olivier Schwartz<sup>18</sup>, Marco Vignuzzi<sup>19</sup>, Christophe d'Enfert<sup>26</sup>, Shaeri Mukherjee<sup>1,17</sup>, Matt Jacobson<sup>6</sup>, Harmit S. Malik<sup>15</sup>, Danica G. Fujimori<sup>1,4,6</sup>, Trey Ideker<sup>27</sup>, Charles S. Craik<sup>6,24</sup>, Stephen Floor<sup>12,24</sup>, James S. Fraser<sup>1,2,9</sup>, John Gross<sup>1,2,6</sup>, Andrej Sali<sup>1,2,6,9</sup>, Tanja Kortemme<sup>1,9,10,2</sup>, Pedro Beltrao<sup>8</sup>, Kevan Shokat<sup>1,4,7</sup>, Brian K. Shoichet<sup>1,2,6</sup>, Nevan J. Krogan<sup>1,2,3,4</sup>




	Virus	TRS
α-CoV	TGEV, FIPV, HCoV-NL63	5'-AACUAAAC-3'
β-CoV	MHV, BCoV, HCoV-HKU1	5'-AAUCUAAAC-3'
	SARS-CoV	5'-AAACGAAC-3'
γ-CoV	IBV	5'-CUUAACAA-3'



**SARS-CoV-2?**

**5'-AAACGAAC-3'**


# SARS-CoV-2 transcripts based on direct RNA-Seq



<https://doi.org/10.1101/2020.03.12.988865>




## Leader to body fusion during negative-strand synthesis




TRS: transcription-regulating sequence

L: leader




B: body



**In the age of CRISPR nothing trumps the awesome power of yeast genetics**



**Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform**  
 bioRxiv <https://doi.org/10.1101/2020.02.21.959817>



Showing 2649 of 2649 genomes sampled between Dec 2019 and Mar 2020.


## Phylogeny

Genotype at S site 614 ^

D

G

RESET LAYOUT



**Do sequence variants influence transmissibility or clinical outcome?**

**Viral load testing**

**Illumina sequencing**

**Long-read sequencing**

**Sequence analysis: SNPs, recombinants, haplotypes**

**Phenotypic analysis of isolated mutants in full virus, replicons, etc.**